{"id":"ipv-at-14-and-fipv-at-22-weeks-rotateq","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling (IPV)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"},{"rate":null,"effect":"Diarrhea (RotaTeq)"},{"rate":null,"effect":"Vomiting (RotaTeq)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPV contains chemically inactivated poliovirus particles that trigger humoral and cell-mediated immune responses without causing disease. RotaTeq is a live attenuated rotavirus vaccine administered orally that replicates in the intestinal tract, inducing mucosal and systemic immunity. Both vaccines work by priming the adaptive immune system to recognize and neutralize the respective pathogens upon natural exposure.","oneSentence":"IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:04.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (IPV component)"},{"name":"Prevention of rotavirus gastroenteritis (RotaTeq component)"}]},"trialDetails":[{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IPV at 14 and fIPV at 22 weeks, RotaTeq","genericName":"IPV at 14 and fIPV at 22 weeks, RotaTeq","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease. Used for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (RotaTeq component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}